Company Overview and News

111
Miners I'm Buying And Why - Part X: FOMO Speculation Vs. Cheap Resource Value; A Baker's Half Dozen Set To Rise - Small-Cap Stock Observer

2018-10-01 seekingalpha - 7
Science and art, or if you prefer skill and luck, are both needed for consistent success in short-term trading to long-term investing. Some deny this and say it's all math, claiming that markets always represent fair value. If so, high-frequency trading algo-bot scalpers will always win, meaning people can never outsmart to beat the market as all opportunities and risks are fully discounted into prices.
STZ.B TWX MEAOF BTR AMZN AABA LVNSF FQM NDM MISVF HVBTF GDX AXXDF STZ TWC PRU SLV BABA ATUSF AAUKF VZ BALMF BB FB DB KGI.DB NFLX GOOG GLD TLRY ALS WEED NAK PMNXF AAPL FQVLF PRU ADV BLKCF DIS KL GDXJ EGO FM KGI MSV KGI.DB.A AAL CGC NDMWF ELD BAR NGLOY

 
A Bull Tackles The Alibaba Short Thesis

2018-09-14 seekingalpha
I examine the core bear arguments against BABA, which are unfortunately left unresolved courtesy of management.
AABA

 
Altaba Becomes An Even More Attractive Proxy For Alibaba

2018-09-12 seekingalpha
Altaba's net asset value per share will increase due to the buybacks, shares look attractive right here.
AABA 4689 YAHOY YAHOF

23
Alibaba, Snap Plunge into Monday’s 52-Week Low Club

2018-09-10 247wallst
September 10, 2018: Here are four stocks trading with heavy volume among 139 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.61 to 1, and on the Nasdaq, advancers led decliners by about 1.11 to 1.
BABA AMAT AABA 4689 YAHOY SNAP YAHOF

135
Tracking David Tepper's Appaloosa Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 10
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
PCG LRCX SYMC KMT CQP CNC VST XOP KEY NRGEO CFIN WPZ BSX CIWV HCA SYK AABA AMAT WMB SUM BTUUQ VNTR BAC TMUSP LNG TMUS OC NRG ALL BABA ETP CZR GOOGL WMIH TERP WFCNP MGM FB PAH AY TMO WDC NVDA GOOG BAC HUN AGN UBS WFC WMIHP GJT XPO CFG BTU ALLY MU VSTE URI DG ULSGF

56
Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 4
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
AKRX VST TWX AU ENL SHPG HAWK VIAB AABA DST OSG.WI AEM INSW MITL AGG SYMX AET FOX TMUSP TMUS RGORF BKD GOLD UTX 2840 TWC OGISD NSW OGSRW MDT SES CZR OGSWW OGISZ XLGLF QCOM INSW.WI FOXA OGSBW ENDP NMRK XL CTL RRS GLD AULGF OSG VRX ODP AGN EGN MON HZNP OSGB DISH OVSPW CMCSA CACQ COL GOLD OVSPA OVSPD VSTE THM BHS

153
Tracking George Soros's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 15
Soros' 13F portfolio value increased from $6.16B to $6.25B this quarter. The number of positions decreased from 219 to 203.
VR LRCX DISCB DISCA NOW TWX DISCK INXN VICI CRM AMZN EQT AABA AET DISC BAC SIGM LGF KWN.CL UTX AIG TWC COUP CZR RNG XLGLF QCOM LIVN FG TIVO WFCNP TMO XL NFLX BAX BAC KW KWN CI GM LBRDB WFC EA C ZAYO CACQ COL LBRDK I TGT LIVN ETFC CNQ CVX LGF.A LBRDA LGF.B SBAC

112
Tracking David Einhorn's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 8
Greenlight's long/short ratio is at 96% long and 75% short compared to 111% long and 82% short last quarter.
TWX AZO MET BLMN DLTR TJX CEIX.WI SFM DSW CLPPZ AABA TWTR VNTR CLPR GLRE CNX.WI ADNT TWC XRX CNDT BHF ROKU GPS ATHN GRBK CCR MDCO NFLX PYPL HUN VOYA ESV ODP AAPL GM CEIX DDS XELA TPR TPX MU DG PRGO TSLA URBN FIVE CNX

26
Snap Stock Has Hope But Not Much Else

2018-08-20 investorplace - 1
I’ve argued since the March 2017 that there’s a simple problem with Snap (NYSE:SNAP) stock: expectations are too high. It’s easy to forget that Snap as a company is less than seven years old.
FB GOOGL TWTR AABA GOOG SNAP

10
Trade of the Day: Altaba Inc (AABA)

2018-08-17 investorplace
To receive further updates on this Altaba Inc (NASDAQ:AABA) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
BABA AABA

33
Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2018 Update

2018-08-14 seekingalpha - 1
David Abrams’ 13F portfolio value increased this quarter from $3.19B to $3.60B. The number of positions increased from 20 to 22.
PCG HCN ENT TWX HCP GOOG GPI QCP ENTWW UHAL KMI AABA WELL BEN BKS CI KMR CCO LAD AET CVB BNED WU TWC GOOGL SPH KMRFZ ORLY

62
Alibaba Stock Is Not as Cheap as You May Have Thought

2018-08-07 investorplace - 3
By any fundamental measure, Alibaba (NYSE:BABA) stock is a steal. Alibaba stock trades at 34x FY18 (ending March 31) adjusted EPS, and 30x free cash flow. That’s after a year where revenue grew 58%, adjusted earnings rose 40%, and free cash flow climbed 44%.
SIRI JD BABA AMZN AABA MKC MSFT GOOG CHD WMT

213
20 Stocks with Big Short Squeeze Potential | InvestorPlace

2018-07-25 investorplace - 9
There’s a fundamental mathematical proposition that makes shorting stocks risky. A short sale — a sale of borrowed stock, made with the intention of buying it back at a cheaper price later — in theory has unlimited losses. A long investor can only lose 100% of her money at most. But a short could lose multiples of the capital originally at risk.
MDGL FB POSTZ SPWR POSTU SKT NFLX AXDX] HRI SIRI MTCH AMZN SPOT AABA AAPL WATT DIS BGS OSTK RDEN SYNA AMC IAC P AXDX ICPT DLGNF PLCE CAR W REV POST MAT BABA HAS T ATHM POSHZ BITA TSLA VZ AAOI STRP DPZ HTZ TUES PZZA

 
Alibaba Is Good, But This Company Is Even Better - And It's Not Amazon

2018-07-20 seekingalpha
Alibaba (BABA) is a high-growth company that is fundamentally strong and that is well positioned in key markets and key technologies. Alibaba is not trading at an overly low valuation, but still looks like a relatively strong investment right here.
AABA 4689 YAHOY YAHOF

2
China Has Fallen: Tencent Is A Conviction Buy

2018-07-16 seekingalpha
This means that there is a growth runway that is being completely missed by the market.
NPSNY FB AABA

AABA : Altaba Stock Analysis and Research Report

2017-11-04 - Asif

Yahoo! Inc (now Altaba), together with its consolidated subsidiarie, is a guide to digital information discovery, focused on informing, connecting, and entertaining its users through its search, communications, and digital content products. By creating highly personalized experiences, the company help users discover the information that matters most to them around the world—on mobile or desktop. The company create value for advertisers with a streamlined, simple advertising technology that leverages Yahoo’s data, content, and technology to connect advertisers with their target audiences. Advertisers can build their businesses through advertising to targeted audiences on its online properties and services (“Yahoo Properties”) and a distribution network of third-party entities (“Affiliates”) who integrate its advertising offerings into their websites or other offerings (“Affiliate sites”). The company's revenue is generated principally from search and display advertising. Altaba is...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to AABA / Altaba Inc on message board site Silicon Investor.

Altaba Inc. (formerly Yahoo) Altaba Inc. (formerly Yahoo) Altaba Inc. (formerly Yahoo)
CUSIP: 984332106